RxDoctor Payments Data

Kathy Foreman

Adult Health · Columbus, OHNPI 1922268150

Payments from drug & device makers

$4,949in general payments, 2019–2025

Across 30 payments — averaging $164.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TG Therapeutics, Inc.$4K
  • Madrigal Pharmaceuticals$584
  • AbbVie$184
  • Ipsen Biopharmaceuticals, Inc$163
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$129
  • Gilead$107
  • plus $124 from 2 others

What the payments were for

  • Consulting fees$1,91339%
  • Travel & lodging$1,74735%
  • Food & beverage$1,29026%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,949 in reported general payments places this provider in the 90th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$24,514
Medicare patients
150
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir12$262,718
RezdiffraResmetirom27$140,750
XifaxanRifaximin44$138,710
VemlidyTenofovir Alafenamide43$55,221
RybelsusSemaglutide18$24,773
OzempicSemaglutide22$24,768
MounjaroTirzepatide19$19,925
Ursodiol66$12,822
ConstuloseLactulose16$1,842
Lactulose26$1,213
Azathioprine47$1,133
Eplerenone18$986
Tenofovir Disoproxil Fumarate23$869
Baclofen16$782
Potassium Chloride24$664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Vemlidy$107$317,93855 claims
Madrigal PharmaceuticalsRezdiffra$584$140,75027 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$129$138,71044 claims
Novo NordiskRybelsus, Ozempic$100$49,54240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,184 adult health providers in Ohio.

Other adult health in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →